Min Yuen Teo1, Jose Mauricio Mota2, Karissa A Whiting3, Han A Li2, Samuel A Funt1, Chung-Han Lee1, David B Solit4, Hikmat Al-Ahmadie5, Matthew I Milowsky6, Arjun V Balar7, Eugene Pietzak8, Guido Dalbagni8, Bernard H Bochner8, Irina Ostrovnaya3, Dean F Bajorin1, Jonathan E Rosenberg1, Gopa Iyer9. 1. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. 2. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 7. Department of Medical Oncology, NYU Langone Health, New York, NY, USA. 8. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: iyerg@mskcc.org.
Abstract
BACKGROUND: Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs). OBJECTIVE: To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC. DESIGN, SETTING, AND PARTICIPANTS: The authors conducted a retrospective review and comparison of patients having (1) MIBC treated with neoadjuvant chemotherapy (NAC), (2) mUC treated with first-line platinum-based chemotherapy (M1 cohort), and (3) MIBC who were from The Cancer Genome Atlas (TCGA). INTERVENTION: Platinum-based chemotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathologic response, recurrence-free (RFS) or progression-free (PFS) survival, and overall survival (OS) were compared between patients with FGFR3 alteration (FGFR3alt) and those without it (FGFR3wild type [FGFR3wt]) in the three cohorts. RESULTS AND LIMITATIONS: Nine of 72 NAC patients (13%) had FGFR3alt, of whom none had pathologic complete response and three had residual non-MIBC (carcinoma in situ, n = 1; pT1, n = 2). FGFR3alt was associated with shorter RFS (hazard ratio, 2.74; p = 0.044) but not OS. Among TCGA patients who underwent adjuvant chemotherapy (n = 74), FGFR3alt patients had shorter RFS as well. Conversely, among chemotherapy-naive TCGA patients, FGFR3alt was associated with longer RFS and OS. In the M1 cohort (FGFR3alt, n = 27; FGFR3wt, n = 81), FGFR3alt was associated with higher rates of pulmonary metastases and nonregional lymphadenopathy. Despite lower response rates among FGFR3alt patients (37% vs 49%; p = 0.056), PFS and OS were not significantly different from FGFR3wt patients. CONCLUSIONS: FGFR3 status is associated with lower responses to platinum-based chemotherapy, which may prompt exploration of nonchemotherapeutic approaches for perioperative management of FGFR3alt urothelial cancers. PATIENT SUMMARY: Approximately 15% of bladder cancers harbor mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. Our findings suggest that FGFR3 mutations might be associated with lower responses and shorter time to recurrence among patients with muscle-invasive bladder cancer who received perioperative platinum-based chemotherapy. FGFR3 status does not significantly impact response to chemotherapy among those with metastatic urothelial cancers.
BACKGROUND: Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs). OBJECTIVE: To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC. DESIGN, SETTING, AND PARTICIPANTS: The authors conducted a retrospective review and comparison of patients having (1) MIBC treated with neoadjuvant chemotherapy (NAC), (2) mUC treated with first-line platinum-based chemotherapy (M1 cohort), and (3) MIBC who were from The Cancer Genome Atlas (TCGA). INTERVENTION: Platinum-based chemotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathologic response, recurrence-free (RFS) or progression-free (PFS) survival, and overall survival (OS) were compared between patients with FGFR3 alteration (FGFR3alt) and those without it (FGFR3wild type [FGFR3wt]) in the three cohorts. RESULTS AND LIMITATIONS: Nine of 72 NAC patients (13%) had FGFR3alt, of whom none had pathologic complete response and three had residual non-MIBC (carcinoma in situ, n = 1; pT1, n = 2). FGFR3alt was associated with shorter RFS (hazard ratio, 2.74; p = 0.044) but not OS. Among TCGA patients who underwent adjuvant chemotherapy (n = 74), FGFR3alt patients had shorter RFS as well. Conversely, among chemotherapy-naive TCGA patients, FGFR3alt was associated with longer RFS and OS. In the M1 cohort (FGFR3alt, n = 27; FGFR3wt, n = 81), FGFR3alt was associated with higher rates of pulmonary metastases and nonregional lymphadenopathy. Despite lower response rates among FGFR3alt patients (37% vs 49%; p = 0.056), PFS and OS were not significantly different from FGFR3wt patients. CONCLUSIONS: FGFR3 status is associated with lower responses to platinum-based chemotherapy, which may prompt exploration of nonchemotherapeutic approaches for perioperative management of FGFR3alt urothelial cancers. PATIENT SUMMARY: Approximately 15% of bladder cancers harbor mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. Our findings suggest that FGFR3 mutations might be associated with lower responses and shorter time to recurrence among patients with muscle-invasive bladder cancer who received perioperative platinum-based chemotherapy. FGFR3 status does not significantly impact response to chemotherapy among those with metastatic urothelial cancers.
Authors: Min Yuen Teo; Richard M Bambury; Emily C Zabor; Emmet Jordan; Hikmat Al-Ahmadie; Mariel E Boyd; Nancy Bouvier; Stephanie A Mullane; Eugene K Cha; Nitin Roper; Irina Ostrovnaya; David M Hyman; Bernard H Bochner; Maria E Arcila; David B Solit; Michael F Berger; Dean F Bajorin; Joaquim Bellmunt; Gopakumar Iyer; Jonathan E Rosenberg Journal: Clin Cancer Res Date: 2017-01-30 Impact factor: 12.531
Authors: Li Wang; Yixuan Gong; Abdel Saci; Peter M Szabo; Alberto Martini; Andrea Necchi; Arlene Siefker-Radtke; Sumanta Pal; Elizabeth R Plimack; John P Sfakianos; Nina Bhardwaj; Amir Horowitz; Adam M Farkas; David Mulholland; Bruce S Fischer; William K Oh; Padmanee Sharma; Jun Zhu; Matthew D Galsky Journal: Eur Urol Date: 2019-07-01 Impact factor: 20.096
Authors: Hans von der Maase; Lisa Sengelov; James T Roberts; Sergio Ricci; Luigi Dogliotti; T Oliver; Malcolm J Moore; Annamaria Zimmermann; Michael Arning Journal: J Clin Oncol Date: 2005-07-20 Impact factor: 44.544
Authors: François Audenet; Sumit Isharwal; Eugene K Cha; Mark T A Donoghue; Esther N Drill; Irina Ostrovnaya; Eugene J Pietzak; John P Sfakianos; Aditya Bagrodia; Paari Murugan; Guido Dalbagni; Timothy F Donahue; Jonathan E Rosenberg; Dean F Bajorin; Maria E Arcila; Jaclyn F Hechtman; Michael F Berger; Barry S Taylor; Hikmat Al-Ahmadie; Gopa Iyer; Bernard H Bochner; Jonathan A Coleman; David B Solit Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531
Authors: A Gordon Robertson; Jaegil Kim; Hikmat Al-Ahmadie; Joaquim Bellmunt; Guangwu Guo; Andrew D Cherniack; Toshinori Hinoue; Peter W Laird; Katherine A Hoadley; Rehan Akbani; Mauro A A Castro; Ewan A Gibb; Rupa S Kanchi; Dmitry A Gordenin; Sachet A Shukla; Francisco Sanchez-Vega; Donna E Hansel; Bogdan A Czerniak; Victor E Reuter; Xiaoping Su; Benilton de Sa Carvalho; Vinicius S Chagas; Karen L Mungall; Sara Sadeghi; Chandra Sekhar Pedamallu; Yiling Lu; Leszek J Klimczak; Jiexin Zhang; Caleb Choo; Akinyemi I Ojesina; Susan Bullman; Kristen M Leraas; Tara M Lichtenberg; Catherine J Wu; Nicholaus Schultz; Gad Getz; Matthew Meyerson; Gordon B Mills; David J McConkey; John N Weinstein; David J Kwiatkowski; Seth P Lerner Journal: Cell Date: 2017-10-05 Impact factor: 41.582
Authors: Gopa Iyer; Arjun V Balar; Matthew I Milowsky; Bernard H Bochner; Guido Dalbagni; S Machele Donat; Harry W Herr; William C Huang; Samir S Taneja; Michael Woods; Irina Ostrovnaya; Hikmat Al-Ahmadie; Maria E Arcila; Jamie C Riches; Andreas Meier; Caitlin Bourque; Maha Shady; Helen Won; Tracy L Rose; William Y Kim; Brooke E Kania; Mariel E Boyd; Catharine K Cipolla; Ashley M Regazzi; Daniela Delbeau; Asia S McCoy; Hebert Alberto Vargas; Michael F Berger; David B Solit; Jonathan E Rosenberg; Dean F Bajorin Journal: J Clin Oncol Date: 2018-05-09 Impact factor: 44.544
Authors: Kathleen A Cronin; Andrew J Lake; Susan Scott; Recinda L Sherman; Anne-Michelle Noone; Nadia Howlader; S Jane Henley; Robert N Anderson; Albert U Firth; Jiemin Ma; Betsy A Kohler; Ahmedin Jemal Journal: Cancer Date: 2018-05-22 Impact factor: 6.860
Authors: Brian D Robinson; Panagiotis J Vlachostergios; Bhavneet Bhinder; Weisi Liu; Kailyn Li; Tyler J Moss; Rohan Bareja; Kyung Park; Peyman Tavassoli; Joanna Cyrta; Scott T Tagawa; David M Nanus; Himisha Beltran; Ana M Molina; Francesca Khani; Juan Miguel Mosquera; Evanguelos Xylinas; Shahrokh F Shariat; Douglas S Scherr; Mark A Rubin; Seth P Lerner; Surena F Matin; Olivier Elemento; Bishoy M Faltas Journal: Nat Commun Date: 2019-07-05 Impact factor: 14.919
Authors: Raie T Bekele; Amruta S Samant; Amin H Nassar; Jonathan So; Elizabeth P Garcia; Catherine R Curran; Justin H Hwang; David L Mayhew; Anwesha Nag; Aaron R Thorner; Judit Börcsök; Zsofia Sztupinszki; Chong-Xian Pan; Joaquim Bellmunt; David J Kwiatkowski; Guru P Sonpavde; Eliezer M Van Allen; Kent W Mouw Journal: J Clin Invest Date: 2021-11-15 Impact factor: 19.456
Authors: Soum D Lokeshwar; Maite Lopez; Semih Sarcan; Karina Aguilar; Daley S Morera; Devin M Shaheen; Bal L Lokeshwar; Vinata B Lokeshwar Journal: Cancers (Basel) Date: 2022-05-24 Impact factor: 6.575